Glimepiride 3mg + Metformin 500mg Tablet in PCD pharma franchise in Hyderabad

Glimepiride 3mg + Metformin 500mg Tablet in pharmaceutical manufacturing company in Mumbai

Glimepiride 3mg + Metformin 500mg Tablet in antidiabetic pharma franchise in Pune

Glimepiride 3mg + Metformin 500mg Tablet in pharma suppliers in Delhi

Glimepiride 3mg + Metformin 500mg Tablet in pharma export companies in Kolkata
Glimepiride 3mg + Metformin 500mg Tablet in pharma franchise opportunities in Bengaluru

Home/Products /glimepiride-i-point-p-point-3mg-metformin-500mg-bi-layered-tablets

Gimtype M3 Tablet

Composition : Glimepiride I.P. 3mg + Metformin Hydrochloride (S.R.) I.P. 500mg Bi-Layered Tablets

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*15

Price : ₹129/-

Gimtype M3 Tablet is a combination of Glimepiride 3mg and Metformin Hydrochloride 500mg in a sustained-release bi-layered formulation. It is designed to offer dual benefits in the management of type 2 diabetes mellitus by improving glycemic control. Glimepiride, a sulfonylurea, stimulates insulin secretion from the pancreas, while Metformin enhances insulin sensitivity and reduces hepatic glucose production. The bi-layered design ensures optimal release for prolonged efficacy.

Read More

About the Product

Gimtype M3 Tablet is a combination of Glimepiride 3mg and Metformin Hydrochloride 500mg in a sustained-release bi-layered formulation. It is designed to offer dual benefits in the management of type 2 diabetes mellitus by improving glycemic control. Glimepiride, a sulfonylurea, stimulates insulin secretion from the pancreas, while Metformin enhances insulin sensitivity and reduces hepatic glucose production. The bi-layered design ensures optimal release for prolonged efficacy.

May cause hypoglycemia, gastrointestinal discomfort, nausea, metallic taste, or weight gain. Metformin may rarely lead to lactic acidosis, a serious but uncommon complication.

Indicated for the management of type 2 diabetes mellitus in adults, especially in patients who require both insulin secretion stimulation and improved insulin sensitivity to control blood glucose levels.

Should be taken with meals to reduce the risk of gastrointestinal side effects. Regular blood sugar monitoring is essential. Not for use in type 1 diabetes or diabetic ketoacidosis. Use with caution in patients with renal or hepatic impairment.

Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation